SUMMARY One hundred and sixty six bone marrow aspirates from children with abdominal neuroblastoma were independently examined for the presence of neuroblastoma cells by conventional haematological staining techniques and by indirect immunofluorescence using one or more of five monoclonal antibodies. Results using the two methods were evaluated by comparison with the results of bone marrow, bone and lymph node biopsy specimens taken at the same time, and in the light of the child's clinical course. One antibody, UJ13A, was found to have 98&5% specificity and 85-7% sensitivity, compared with sensitivities for conventional staining of 50% for aspirate alone and of aspirate or trephine biopsy specimen of 71 4%. The remaining antibodies UJ 127/11, UJ223/8, UJ181/4 and UJ167/1 1, with specificities in the range 94-99%, were found to have sensitivities in the range 47-61%, lower than the sensitivity of conventionally stained aspirate or trephine biopsy specimen. Routine immunofluorescence staining with monoclonal antibody UJ1 3A should increase the sensitivity of detection of metastatic neuroblastoma.
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Detection of bone marrow infiltration is of clinical importance in the management of children with neuroblastoma for the following reasons:
(i) at diagnosis to determine stage of disease and hence treatment and prognosis; (ii) during treatment to assess response; (iii) before marrow harvest for autologous marrow rescue; (iv) after completion of treatment to confirm or refute suspected relapse. As part of the routine assessment of each bone marrow aspirate spread films of aspirated material were stained with May-Grunwald-Giemsa and were examined for the presence of tumour cells using light microscopy by an experienced haematologist. As the aim of the study was to establish the additional contribution that might be made to our routine practice by monoclonal antibody studies no additional blind review was performed for purposes of the study; similarly, trephine biopsy specimens were examined by an experienced histopathologist according to routine procedures but without further blind review.
For monoclonal antibody studies, 0-2-05 ml of aspirate were added to 5 ml of tissue culture medium (Roswell Park Memorial Institute) containing 0-5 ml of 1/1000 preservative-free heparin. Nucleated cells were separated by layering the sample onto 5 ml Ficoll and centrifuging at 150 g for 10 minutes. Cells were counted using a Neubauer counting chamber, and I x 106 nucleated cells were incubated with each individual monoclonal antibody in an LP3 tube. The number of antibodies used to test the cells therefore depended on the total cell count. the individual antibody result was assessed in relation to the results of trephine, lymph node, and bone biopsy specimens and in relation to clinical outcome as follows.
Positive antibody results with negative conventional results were classified as true positive if there was evidence from aspirate or trephine biopsy specimen of marrow disease at another site or evidence from lymph node or bone histology of disseminated disease. They were also classified as true positive if positive in children with disseminated disease (shown by conventional techniques at diagnosis) who had received only two courses of chemotherapy. They were classified as false positive if occurring in children off treatment without any other evidence of disease who sub- be true negative for both conventional staining and immunofluorescence. Table 4 shows the results obtained for conventional staining and for each antibody together with individual sensitivities and specificities.
Discussion
Favrot et al showed that in some patients with neuroblastoma bone marrow aspirates were positive by antibody testing in the absence of other evidence of marrow disease. 4 In six of these patients this antibody positivity correlated with subsequent relapse despite treatment: in the remaining four insufficient follow up information was available for assessment. If in the absence of evidence of marrow infiltration by conventional examination of marrow aspirate and marrow biopsy specimen antibody positivity is to be accepted as evidence in its own right of marrow infiltration, the antibody must show a high specificity for neuroblastoma cells. If such evidence is to be useful to the clinician the sensitivity of the antibody method must be at least as great as that of conventional methods. This retrospective study suggests that one antibody in particular, UJI 3A, in addition to showing a high specificity for neuroblastoma cells in bone marrow, may also have a sensitivity greater than conventional morphological methods. In this study assessment was based on the presence or absence of other evidence of disseminated disease and on clinical outcome, but in future studies it may be possible to compare the antibody results with those of neurone specific enolase staining,9 in situ hybridisation for N-myc amplification,'0 or of cell culture techniques."
The remaining four antibodies used in this study showed good specificity for neuroblastoma cells but less sensitivity than either conventional staining or UJ I 3A. This lesser sensitivity might relate to variation of antigen expression in different neuroblastomas, as suggested by the varying patterns of antibody positivity shown by the tumours themselves.'2 Although the numbers ofobservations from which the sensitivities of these antibodies were calculated were small, the results suggest that use of a panel of antibodies, our current practice,3 increases the specificity of detection by this method but not the sensitivity. The importance of this observation varies with the particular context in which the marrow is being examined: thus at initial diagnosis or at diagnosis of relapse a high level of specificity is desirable while in the assessment of response and particularly before marrow harvest a high level of sensitivity is more important.
We conclude that monoclonal antibodies have increased our ability to detect and characterise neuroblastoma cells in bone marrow and that their use can improve staging and management of this disease.
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